Bioelectric Medicine Market Report 2026

The bioelectric medicine market size has grown strongly in recent years. It will grow from $26.81 billion in 2025 to $29.2 billion in 2026 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to increasing prevalence of neurological disorders, rising adoption of cardiac rhythm management devices, advancements in neuromodulation technologies, growing acceptance of device-based therapies, improvements in implantable device safety.

The bioelectric medicine market size is expected to see strong growth in the next few years. It will grow to $39.19 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to increasing demand for personalized medicine, expansion of minimally invasive treatment options, rising investments in electroceutical research, growing integration of digital health platforms, increasing focus on long-term disease management solutions. Major trends in the forecast period include increasing adoption of implantable neuromodulation devices, rising use of non-invasive electroceutical therapies, growing integration of AI-guided stimulation protocols, expansion of personalized bioelectric treatments, enhanced focus on chronic disease management.

The rising healthcare expenditure is expected to drive the growth of the bioelectric medicine market in the coming years. Healthcare expenditure refers to the total amount of money allocated to healthcare services and resources over a specific period. This increase in healthcare spending is driven by factors such as an aging population, advancements in medical technology, and a growing prevalence of chronic diseases. Higher healthcare expenditure positively influences bioelectric medicine by enabling greater investment in the research, development, and adoption of innovative bioelectric therapies. For example, in May 2024, according to the Office for National Statistics, a UK-based national statistical institute, healthcare expenditure in the UK reached approximately $382.5 billion (£292 billion) in 2023, up from $370.7 billion (£283 billion) in 2022. Thus, the rising healthcare expenditure is expected to propel the bioelectric medicine market forward.

Major companies in the bioelectric medicine market are concentrating on technological innovations, such as software-enabled general wellness bioelectric medicines, to strengthen their competitive position. This software-enabled general wellness medicine provides users with accurate guidance for deep brain stimulation therapy procedures and supports surgical planning, intraoperative electrode placement, and personalized programming for deep brain stimulation therapy. For example, in July 2023, Boston Scientific Corporation, a US-based bioelectric medicine and wellness company, announced that its Vercise Neural Navigator 5 Software had received approval from the US FDA. The software offers advanced capabilities for precise targeting and programming of deep brain stimulation (DBS) therapy. By integrating imaging data with stimulation parameters, it enables tailored treatment for neurological disorders. This ensures accurate electrode placement, guided surgical planning, and customized programming, ultimately improving treatment outcomes and patient satisfaction.

In May 2025, electroCore, Inc., a U.S.-based provider of noninvasive bioelectronic therapy and wellness devices, acquired NeuroMetrix, Inc., for US $4.49 per share in cash along with contingent value rights. Through this acquisition, electroCore aims to broaden its technology portfolio in noninvasive neuromodulation and accelerate market expansion in chronic pain and wellness segments. NeuroMetrix is a U.S.-based developer of wearable neurotechnology devices, offering the Quell platform for chronic pain management and DPNCheck diagnostics for peripheral neuropathy.

Major companies operating in the bioelectric medicine market are Abbott Laboratories, Medtronic PLC, Boston Scientific Corporation, Biotronik SE & Co KG, Cochlear Ltd, LivaNova PLC, Inspire Medical Systems Inc, Nevro Corporation, Axonics Inc, NeuroPace Inc, Zynex Inc, ElectroCore Inc, NeuroMetrix Inc, Soterix Medical Inc, Galvani Bioelectronics, MicroTransponder Inc, BioElectronics Corporation, Cerbomed GmbH, SetPoint Medical, Blackrock Neurotech, ONWARD Medical, Nalu Medical.

North America was the largest region in the bioelectric medicine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bioelectric medicine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bioelectric medicine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the bioelectric medicine market by increasing costs of imported semiconductors, microelectronics, batteries, sensors, and precision components used in implantable and non-invasive electroceutical devices. North America and Europe are most affected due to reliance on advanced imported electronics, while Asia-Pacific faces pricing pressure in device manufacturing and exports. These tariffs are raising device costs and impacting hospital procurement budgets. At the same time, they are encouraging localized manufacturing, regional component sourcing, and innovation in cost-optimized bioelectric medical devices.

The bioelectric medicine market research report is one of a series of new reports that provides bioelectric medicine market statistics, including bioelectric medicine industry global market size, regional shares, competitors with a bioelectric medicine market share, detailed bioelectric medicine market segments, market trends and opportunities, and any further data you may need to thrive in the bioelectric medicine industry. This bioelectric medicine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Bioelectric medicine, also referred to as electroceuticals or bioelectronic medicine, is a branch of medical science that focuses on using electrical signals to regulate the body's nervous system to address various diseases and conditions. This method employs devices that deliver precise electrical impulses to affect nerve activity, restore normal function, and support healing in specific areas of the body.

The primary types of bioelectric medicine include implantable electroceutical devices and non-invasive electroceutical devices. Implantable electroceutical devices are those inserted into the body to provide therapeutic electrical stimulation for medical purposes. These products include implantable cardioverter-defibrillators, cardiac pacemakers, cochlear implants, spinal cord stimulators, deep brain stimulators, transcutaneous electrical nerve stimulators (TENS), sacral nerve stimulators, vagus nerve stimulators, and others, with applications such as arrhythmia, pain management, sensorineural hearing loss, Parkinson’s disease, tremor, depression, treatment-resistant depression, and more. The end users include hospitals and other healthcare providers.

The bioelectric medicine market consists of sales of peripheral nerve stimulation (PNS) devices, neuroprosthetics, functional electrical stimulation (FES) Devices, electroretinography (ERG) devices. This market includes electroceutical devices for wound healing, non-invasive brain stimulation devices, and wearable bioelectric monitoring devices. Values in this market represent the factory gate values, including the goods sold by manufacturers or creators to downstream entities or directly to end customers. It encapsulates the value of goods and related services offered by the creators of these medicinal devices.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.